
    
      This is a prospective, open-label, and multi-centered feasibility registry (single arm
      study). Approximately 36 subjects with prohibitive risk degenerative mitral regurgitation
      (DMR) who receive at least 1 commercial MitraClip will be registered at up to 10 US sites.
    
  